Chan, M K <br/><br/>
Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions.  [electronic resource] 

 -  Metabolism: clinical and experimental  Oct 1989 
 - 939-45 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0026-0495 
<br/><br/><label>Standard No.: </label>10.1016/0026-0495(89)90003-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Apolipoprotein A-I<br/>Apolipoproteins A--metabolism<br/>Apolipoproteins B--metabolism<br/>Cholesterol--metabolism<br/>Cholesterol, HDL--metabolism<br/>Cholesterol, LDL--metabolism<br/>Drug Evaluation<br/>Female<br/>Gemfibrozil--administration & dosage<br/>Humans<br/>Hyperlipidemias--prevention & control<br/>Lipid Metabolism<br/>Lipoprotein Lipase--metabolism<br/>Lipoproteins, HDL--metabolism<br/>Liver--enzymology<br/>Male<br/>Middle Aged<br/>Peritoneal Dialysis, Continuous Ambulatory--adverse effects<br/>Time Factors<br/>Triglycerides--metabolism